ALX Oncology Holdings Inc. (ALXO, Financials) saw its stock price fall 15.8% to $1.52 as of 2:32 p.m. GMT-5 on Thursday, despite announcing positive updated results from its ASPEN-06 Phase 2 clinical trial.
Presenting at the 2025 American Society of Clinical Oncology Gastrointestinal tumors Symposium, the findings showed the potential of its experimental CD47-blocking therapy, evorpacept, to enhance outcomes for patients with HER2-positive stomach or gastroesophageal junction tumors.
Referred known as ETRP, the study assessed evorpacept versus a control group receiving trastuzumab, ramucirumab, and paclitaxel in combination. Evorpacept attained an overall response rate of 48.9%, almost tripling the 24.5% ORR seen in the control group among patients with verified HER2-positive expression. Median progression-free survival also increased to 7.5 months with evoracept from 6.7 months in the control group.
In those with verified HER2-positive expression, the therapy also showed a median duration of response of 15.7 months, much exceeding the 9.1 months attained by the control group. Safety records showed that evorpacept was typically well tolerated and that the adverse event profile matched the control schedule.
Presenting the results, Dr. Kohei Shitara highlighted the importance of evorpacept's effectiveness especially for patients who had already had HER2-targeted treatments. Chief Medical Officer of ALX Oncology, Dr. Alan Sandler, underlined the design of the treatment, which combines anti-HER2 antibodies efficiently to improve results.
For the second-line treatment of HER2-positive stomach and gastroesophageal junction tumors, the U.S. Food and Drug Administration has assigned Fast Track designation to evoracept. For this indication, the treatment also boasts Orphan Drug Designation from the FDA and the European Commission.
Confident in evorpacept's potential as a therapeutic choice for patients, ALX Oncology intends to engage regulatory talks with the FDA.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。